Compound Therapeutics Appoints Dr. John Mendlein As CEO; Biotech Executive To Accelerate Partnering And Development Of A Breakthrough Class Of Pharmaceuticals
10/19/2005 5:08:55 PM
WALTHAM, Mass.--(BUSINESS WIRE)--June 15, 2005--Compound Therapeutics announced today that Dr. John Mendlein has been appointed chief executive officer to accelerate the development of the Company's oncology product pipeline based on a new, proprietary class of pharmaceuticals, AdNectins. Dr. Mendlein has over 20 years of experience in the pharmaceutical industry, including biotechnology and top tier pharmaceutical companies.
Compound Therapeutics' founding CEO, Dr. Frank Lee, will continue at the Company as chairman of the board, and Dr. L. Patrick Gage, former executive chairman, transitions to non-executive director.
comments powered by